---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018795"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T15:22:21.408554+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q1 loss $0.81; China roxadustat sales up 47%; pamrevlumab Ph3 data expected in 2023

## Summary
- Net loss $76.7M ($0.81/sh) vs $63.2M ($0.68/sh) in Q1 2022.
- Total revenue $36.2M, down from $60.8M (prior year included $25M milestone).
- China roxadustat net product revenue $24.2M (+28% YoY); total China sales $64.1M (+47%).
- Completed non-dilutive term loan facility of up to $150M with Morgan Stanley Tactical Value.
- Topline data from four Phase 3 trials (pamrevlumab in DMD, IPF, LAPC; roxadustat in CIA) expected through 3Q 2023.

## SEC filing metadata
- accession: 0000950170-23-018795
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/0000950170-23-018795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/fgen-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018795
- JSON: https://secwatch.observer/filing/0000950170-23-018795.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018795.txt

## Key facts
- Earnings Releases
  KYNTRA BIO, INC. reported financial results for the first quarter 2023.
  - Period: the first quarter 2023
  - Result: reported results
  source text: On May 8, 2023, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/0000950170-23-018795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.